Newborn Screening Market Analysis by Industry Perspective, Comprehensive Analysis, Growth and Forecast
 |
| Newborn Screening Market |
Newborn screening is one of the most
significant advances in child health over the last century, and the
technologies used in newborn screening have advanced significantly. The ability
to detect multiple compounds diagnostic of different inborn errors of
metabolism in neo-natal dried blood specimens has enabled the rapid pace of
development in the field of newborn screening. Following the success of the
newborn screening market in phenylketonuria, experts in this field are
optimistic that additional health benefits will emerge in the future.
Furthermore, the commercialization of hybrid
instruments is one of the most exciting and powerful advancements in this
field. To gain a foothold in the market, manufacturers are focusing on high
sensitivity, resolution, throughput, and cost-effectiveness. As a result, many
companies have been influenced by emerging technologies and have implemented
numerous new clinical testing platforms.
Since the last five years, most screening
programs have used tandem mass spectrometry (MS/MS) as their primary tool for
analyzing blood spots. TMS has transformed the newborn screening market. It has
decreased false-positive results and simplified the screening process. Over
forty metabolic conditions can be screened for using this test. Prior to the
use of MS/MS for newborn screening, each condition required a separate
bacterial assay.
Except
for endocrine disorders (such as congenital hypothyroidism and congenital
adrenal hyperplasia), hemoglobin disorders (such as sickle cell disease,
S-beta thalassemia, and sickle-C disease), and a few others (such as
biotinidase, cystic fibrosis, transferase-deficient galactosemia, and hearing
disorders), no other conditions require separate testing. The advancement of
technology has also aided in the expansion
of the newborn screening market to include the detection of additional
disorders.
Thus, advances in technology and the
expansion of the uniform newborn screening panel of diseases have resulted in
earlier life-saving treatment and intervention for at least 12,000 additional
newborns with selected genetic, hearing, and endocrine disorders in the United
States each year.
Source-
1)
Comments
Post a Comment